Dr Li Zhang speaks to ecancer about the phase 3 OptiTROP-Lung04 study. This study evaluated sacituzumab tirumotecan (Sac-TMT), a TROP2-directed antibody-drug conjugate, compared to standard platinum-based chemotherapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC) resistant to EGFR-TKIs.

Among 376 patients, Sac-TMT significantly improved median progression-free survival (8.3 vs 4.3 months; HR 0.49; P<0.0001) and demonstrated superior overall survival compared to chemotherapy. Objective response rates were also higher with Sac-TMT (60.6% vs 43.1%), and safety was manageable with no cases of drug-related interstitial lung disease or pneumonitis.

Dr Zhang says that these results position Sac-TMT as a potential new standard of care for EGFR-TKI resistant NSCLC.

See experts discuss more on NSCLC here.